Corvus Pharmaceuticals has faced volatility due to mixed clinical data and given the current valuation and market ...

Corvus Pharmaceuticals suffered lately, especially after it announced in December 2024 its early AD data. Check out why I ...

Q4 2024 Earnings Call Transcript March 25, 2025 Corvus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a ...

Insiders who purchased Corvus Pharmaceuticals, Inc. ( NASDAQ:CRVS ) shares in the past 12 months are unlikely to ...

Reports as of December 31, Corvus had cash, cash equivalents and marketable securities of $52.M as compared to $27.1M as of December 31, 2023.

Corvus Pharmaceuticals stock opened at $3.35 on Wednesday. The stock has a market cap of $215.26 million, a PE ratio of -3.60 and a beta of 0.91. The business’s 50-day moving average price is $4 ...

CORVUS PHARMACEUTICALS ($CRVS) posted quarterly earnings results on Tuesday, March 25th. The company reported earnings of -$0.18 per share, missing estimates of -$0. ...

SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a ...

On a per-share basis, the Burlingame, California-based company said it had a loss of 18 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by ...

Thank you for standing by and welcome to the Corvus Pharmaceuticals fourth-quarter and full-year 2024 business update and financial results conference call. (Operator Instructions) It is now my ...